Given Imaging sees 2013 growth

The pill camera company's fourth quarter net profit rose 3% to $7.9 million on $48.7 million revenue.

Pill camera developer Given Imaging Ltd. (Nasdaq: GIVN; TASE: GIVN) reported net profit growth on flat revenue for the fourth quarter and full year of 2012, but forecasts growth in 2013, despite reducing its profit forecast because of a new tax in the US.

Fourth quarter revenue edged up $48.7 million from $48.5 million for the corresponding quarter 2011. GAAP-based net profit fell to $5.1 million ($0.16 per share) for the fourth quarter from $5.6 million for the corresponding quarter, but non-GAAP net profit rose 3% to $7.9 million ($0.25 per share) from $7.7 million.

Full-year revenue rose 1% to $180.5 million from $178 million in 2011. GAAP-based net profit rose 20% to $14.4 million ($0.45 per share) in 2012 from $12 million in 2011, and non-GAAP net profit rose 12% to $22.6 million ($0.72 per share) from $20.1 million.

Given Imaging beat the analysts' 2012 earnings per share consensus of $0.68, but missed the revenue consensus of $202.3 million, but beat the fourth quarter earnings per share consensus of $0.15 and revenue consensus of $48.2 million.

In its full-year guidance for 2013, Given Imaging forecasts GAAP-based earnings per share of $0.55-0.63 and non-GAAP earnings per share of $0.80-0.88 on $195-205 million revenue. It reduced its earnings per share estimate by $0.08 due to the newly imposed Medical Device Tax in the US. The guidance is below the analysts' revenue consensus of $234.6 million, but meets the earnings per share consensus of $0.85.

Cash flow from operations totaled $11 million for the fourth quarter and $27.8 million in 2012, and the company had $124.1 million in cash and cash equivalents at the end of the year.

A 6% increase in sales in the Americas to $115.1 million in 2012 from $108.8 million in 2011, was offset by a 5% drop in Europe, Middle East and Africa sales to $42.9 million from $45.1 million, and a 6% drop in Asia-Pacific to $22.5 million from to $24 million, due to weaker sales in China, Japan, and Australia. Global sales of functional GI diagnostics products rose 8% to $53 million in 2012 from $48.2 million in 2011.

Global PillCam SB (small bowel) sales rose 2% to 235,700 capsules in 2012 from 232,200 capsules in 2011. Higher sales in the Americas and Asia-Pacific were offset by lower sales in Europe and the Middle East.

"We expect 2013 to be a pivotal year for Given Imaging and our goal is to return to double-digit revenue growth as we expand the market for our comprehensive line of devices to visualize, detect, and monitor disorders in the digestive tract and introduce new, innovative products, including our next-generation capsule endoscope for the small bowel, PillCam SB3. We plan to launch PillCam SB3 in Europe this quarter and in the US later this year," said Given Imaging president and CEO Homi Shamir.

Published by Globes [online], Israel business news - - on February 13, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס